Barclays Raises Hims & Hers Target After Novo Deal Clears
Barclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
See what results to expect from zero based budgeting and how to monitor progress with clear, actionable metrics.
19,375 articlesBarclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
Bumble reports softer user growth and a hefty impairment bill, even as cash flow improves. The AI-driven reboot is dr...
U.S.-China talks open in Paris as officials prepare for a high-stakes Xi summit. The discussions, led by bessent lead...
Pollo Loco's 2025 earnings picture blends value-driven demand with store growth and efficiency. This article breaks d...
Ford’s 5% yield draws income investors, but the path to EV profitability and a big impairment bill raise questions ab...
Dreaming of leaving the workforce early? This guide distills two concrete moves that can make early retirement within...
Two popular consumer staples ETFs—FSTA and FTXG—offer different routes to defense in a volatile market. This guide br...
Quant funds are piloting a data-pruning approach named test delete to improve backtest robustness as markets remain v...
As Zillow prepares for 2026 earnings season, investors crave clarity on growth, margins, and how the housing cycle co...
Stocks all-time highs still attract buyers as earnings momentum and AI-driven demand support another leg up. Here's t...
Geospace's 2026 earnings trajectory shows modest top-line growth, improving margins, and a healthy backlog. This deep...
The AI chip rally is shifting from training to real-world inference. This article explains why the next phase chip su...